Browsing by Author "Halpin, DMG"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
    Bousquet, J; Melén, E; Haahtela, T; Koppelman, GH; Togias, A; Valenta, R; Akdis, CA; Czarlewski, W; Rothenberg, M; Valiulis, A; Wickman, M; Akdis, M; Aguilar, D; Bedbrook, A; Bindslev-Jensen, C; Bosnic-Anticevich, S; Boulet, LP; Brightling, CE; Brussino, L; Burte, E; Bustamante, M; Canonica, GW; Cecchi, L; Celedon, JC; Loureiro, CC; Costa, E; Cruz, AA; Erhola, M; Gemicioglu, B; Fokkens, WJ; Garcia-Aymerich, J; Guerra, S; Heinrich, J; Ivancevich, JC; Keil, T; Klimek, L; Kuna, P; Kupczyk, M; Kvedariene, V; Larenas-Linnemann, DE; Lemonnier, N; Carlsen, KCL; Louis, R; Makela, M; Makris, M; Maurer, M; Momas, I; Morais-Almeida, M; Mullol, J; Naclerio, RN; Nadeau, K; Nadif, R; Niedoszytko, M; Okamoto, Y; Ollert, M; Papadopoulos, NG; Passalacqua, G; Patella, V; Pawankar, R; Pham-Thi, N; Pfaar, O; Regateiro, FS; Ring, J; Rouadi, PW; Samolinski, B; Sastre, J; Savouré, M; Scichilone, N; Shamji, MH; Sheikh, A; Siroux, V; Sousa-Pinto, B; Standl, M; Sunyer, J; Taborda-Barata, L; Toppila-Salmi, S; Torres, MJ; Tsiligianni, I; Valovirta, E; Vandenplas, O; Ventura, MT; Weiss, S; Yorgancioglu, A; Zhang, L; Latiff, AHA; Aberer, W; Agache, I; Al-Ahmad, M; Alobid, I; Ansotegui, IJ; Arshad, SH; Asayag, E; Barbara, C; Baharudin, A; Battur, L; Bennoor, KS; Berghea, EC; Bergmann, KC; Bernstein, D; Bewick, M; Blain, H; Bonini, M; Braido, F; Buhl, R; Bumbacea, RS; Bush, A; Calderon, M; Calvo-Gil, M; Camargos, P; Caraballo, L; Cardona, V; Carr, W; Carreiro-Martins, P; Casale, T; Sarabia, AMC; Chandrasekharan, R; Charpin, D; Chen, YZ; Cherrez-Ojeda, I; Chivato, T; Chkhartishvili, E; Christoff, G; Chu, DK; Cingi, C; de Sousa, JC; Corrigan, C; Custovic, A; D'Amato, G; Del Giacco, S; De Blay, F; Devillier, P; Didier, A; Teixeira, MD; Dokic, D; Douagui, H; Doulaptsi, M; Durham, S; Dykewicz, M; Eiwegger, T; El-Sayed, ZA; Emuzyte, R; Fiocchi, A; Fyhrquist, N; Gomez, RM; Gotua, M; Guzman, MA; Hagemann, J; Hamamah, S; Halken, S; Halpin, DMG; Hofmann, M; Hossny, E; Hrubisko, M; Irani, C; Ispayeva, Z; Jares, E; Jartti, T; Jassem, E; Julge, K; Just, J; Jutel, M; Kaidashev, I; Kalayci, O; Kalyoncu, AF; Kardas, P; Kirenga, B; Kraxner, H; Kull, I; Kulus, M; La Grutta, S; Lau, S; Thi, LL; Levin, M; Lipworth, B; Lourenço, O; Mahboub, B; Martinez-Infante, E; Matricardi, P; Miculinic, N; Migueres, N; Mihaltan, F; Mohammad, Y; Moniuszko, M; Montefort, S; Neffen, H; Nekam, K; Nunes, E; Tshipukane, DN; O'Hehir, R; Ogulur, I; Ohta, K; Okubo, K; Ouedraogo, S; Olze, H; Pali-Schöll, I; Palomares, O; Palosuo, K; Panaitescu, C; Panzner, P; Park, HS; Pitsios, C; Plavec, D; Popov, TA; Puggioni, F; Quirce, S; Recto, M; Repka-Ramirez, MS; Cordeiro, CR; Roche, N; Rodriguez-Gonzalez, M; Romantowski, J; Rosario, N; Rottem, M; Sagara, H; Serpa, FS; Sayah, Z; Scheire, S; Schmid-Grendelmeier, P; Sisul, JC; Sole, D; Soto-Martinez, M; Sova, M; Sperl, A; Spranger, O; Stelmach, R; Ulrik, CS; Thomas, M; To, T; Todo-Bom, A; Tomazic, PV; Urrutia-Pereira, M; Valentin-Rostan, M; Van Ganse, E; van Hage, M; Vasankari, T; Vichyanond, P; Viegi, G; Wallace, D; Wang, DY; Williams, S; Worm, M; Yiallouros, P; Yusuf, O; Zaitoun, F; Zernotti, M; Zidarn, M; Zuberbier, J; Fonseca, JA; Zuberbier, T; Anto, JM
    Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of one-airway-one-disease, coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the Epithelial Barrier Hypothesis. This review determined that the one-airway-one-disease concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme allergic (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.
  • No Thumbnail Available
    Item
    Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
    Lu, WY; Aarsand, R; Schotte, K; Han, J; Lebedeva, E; Tsoy, E; Maglakelidze, N; Soriano, JB; Bill, W; Halpin, DMG; Rivera, MP; Fong, KM; Kathuria, H; Yorgancioglu, A; Gappa, M; Lam, DC; Rylance, S; Sohal, SS
    The WHO recently published a Tobacco Knowledge Summary (TKS) synthesizing current evidence on tobacco and COPD, aiming to raise awareness among a broad audience of health care professionals. Furthermore, it can be used as an advocacy tool in the fight for tobacco control and prevention of tobacco-related disease. This article builds on the evidence presented in the TKS, with a greater level of detail intended for a lung-specialist audience. Pulmonologists have a vital role to play in advocating for the health of their patients and the wider population by sharing five key messages: (1) Smoking is the leading cause of COPD in high-income countries, contributing to approximately 70% of cases. Quitting tobacco is an essential step toward better lung health. (2) People with COPD face a significantly higher risk of developing lung cancer. Smoking cessation is a powerful measure to reduce cancer risk. (3) Cardiovascular disease, lung cancer and type-2 diabetes are common comorbidities in people with COPD. Quitting smoking not only improves COPD management, but also reduces the risk of developing these coexisting conditions. (4) Tobacco smoke also significantly impacts children's lung growth and development, increasing the risk of respiratory infections, asthma and up to ten other conditions, and COPD later in life. Governments should implement effective tobacco control measures to protect vulnerable populations. (5) The tobacco industry's aggressive strategies in the marketing of nicotine delivery systems and all tobacco products specifically target children, adolescents, and young adults. Protecting our youth from these harmful tactics is a top priority.
  • No Thumbnail Available
    Item
    Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries
    Rylance, S; Bateman, ED; Boulet, L; Cohen, M; El Sony, A; Halpin, DMG; Khoo, EM; Marks, GB; Masekela, R; Mikkelsen, B; Mortimer, KJ; Muhwa, JC; Da Cunha, IN; Sajnic, A; Salvi, S; Slama, S; Winders, T; Yorgancioglu, A; Zar, HJ
  • No Thumbnail Available
    Item
    Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries
    Stolbrink, M; Chinouya, MJ; Jayasooriya, S; Nightingale, R; Evans-Hill, L; Allan, K; Allen, H; Balen, J; Beacon, T; Bissell, K; Chakaya, J; Chiang, CY; Cohen, M; Devereux, G; El Sony, A; Halpin, DMG; Hurst, JR; Kiprop, C; Lawson, A; Mace, C; Makhanu, A; Makokha, P; Masekela, R; Meme, H; Khoo, EM; Nantanda, R; Pasternak, S; Perrin, C; Reddel, H; Rylance, S; Schweikert, P; Were, C; Williams, S; Winders, T; Yorgancioglu, A; Marks, GB; Mortimer, K
    BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low-and middle-income countries (LMICs), causing avoidable morbidity and mortality. The Inter-national Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi -stake-holder, collaborative efforts.